Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

Asker Healthcare, Audiocast, Q2'25

By Inderes7/22/2025, 8:00 AM
Asker Healthcare

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Johan Falk
00:00 - 06:54

Thank you very much. Um, and welcome to the Q2 report from Asker Healthcare Group. This is our second report in the listed environment. Um, for me, it's, uh, my 13th year. So it's more of the same. No drama and a steady performance throughout the first part of the year. Makes me proud of what we do. If we, um, have a look at the second quarter isolated, we see a solid performance from the 50 plus companies across 17 markets. However, we had a little bit of a headwind from the translation effects of FX. The adjusted EBITDA is actually growing by 15%, but a 3% FX effect brings it down to 12%. So good. Solid performance. Um, however, the North region had a little bit of a drawback from product sales. We're going to come back to that later on. So they faced very strong quarters last year. But the underlying business is in good shape. So, all in all, adjusted EBITDA, which is our most important KPI, increased by 12% after accounting for the 3% FX effect impact. Good to see that organically. We're growing 7% and acquisitions added another 8%. Net sales were up 9% to 4 billion, also impacted by a -4% effect from exchange rates. Our EBITDA margin was up to 9.5. So we see it's steadily growing towards our targets of 10% in the mid-term. This quarter has been, I can say, back to normal, and we see an increasing inflow of potential targets in acquisitions. In my 13 years here, we've never seen such a good pipeline. And I think it's partly because we are a listed company and market leader in Europe, which is why companies and entrepreneurs are turning to us to be part of the Asker story and improve the healthcare system. So to me, this is the most important message that we have a fantastic market to act on, regardless of the financial climate and uncertainty. Medical supplies, devices, and equipment are needed and we are providing them across Europe, which gives us a fantastic feeling to see our entrepreneurs help the healthcare sector. I believe that is also the reason why companies approach us and wish to join the group, as it contributes to creating shareholder value. The most important aspect is that we can be a larger group and improve healthcare while also creating value at the same time. So it feels really, really good. Um, we have a net debt, uh, over EBITDA, uh, that continues to be low. So it gives us the firepower to continue acquiring companies. And we describe our business model as, you know, the twin engine of organic growth. Priority number one. But adding new companies to the group is equally important. So both of these engines are performing well during this time. Looking at this business, of course, it can fluctuate by approximately 3% up or down each quarter. But over time, both backwards and forwards, we see the performance that we are here to deliver. So, 20% adjusted EBITDA growth for the past 12 months. We're keeping our overall EBITDA over net working capital at 65%, which is very good to see. The last 12 months have been at 9.2, a little bit stronger in this quarter, which is usually a stronger quarter as well. But it's going in the right direction, which is good. And then the low leverage is giving us good firepower for the future. So looking at the acquisition, then, I mean, as you all can imagine, the process of going from a private environment to a listed environment takes some energy from me and my fantastic team, as well as the managers out there. So now we are back on track and, as I mentioned, we are seeing the best pipeline so far in my 13 years here. We are now in a fantastic situation where we can pick and choose the best ones. We usually buy 50% of the companies we evaluate, but now I think we're down to a lower percentage. So our limitation is now the financial targets that we have set up, and picking the best companies that perform the best, and welcome them to the group. So during this quarter, we bought four companies and actually added one more up until today after the quarter period ended. So five companies, um, and six in total. The first half of the year gives me confidence for the coming months and years to come. And we have, um, we're not able to go through all the companies in every meeting, but we'll highlight one or two of them every quarter. This time we have chosen to highlight Scan Modul, a company that is based in the Netherlands. But they act in ten different markets across Europe. They have a long history of expertise in ensuring that medical supplies and equipment are stored in the best possible way in different hospitals and healthcare units. And this is, to me, a little bit of the last mile, giving access to these important critical products and services. So Scan Modul has a long history of customer relationships and knowledge about how to make sure that the products are at the right point, at the right time, storing them and keeping track of dates and all of these possible things you imagine you need to perform good healthcare. So this is what we call a new type of company, not a platform as such, that could give us continuous growth going forward. And we have, as you know, a strategy to buy 10 to 20 new companies a year using our free cash flow to buy companies. But once in a while, we tend to buy a little bit larger companies. Um, Scan Modul is a little bit larger and a little bit of a strategic acquisition for us. It's very good to see, and hopefully, you can create good growth going forward. With that, I'll leave the word to Tom.

Thomas Moss
06:55 - 15:16

Great. Thank you, Johan. Uh, we can dive a little bit more into some of the financials. So, if I start with the group overview here on page six. Uh, what you see is very much in line with what Johan described. Solid revenue and EBITDA growth and a slightly stronger margin coming through in Q2. So, the net sales for the group in Q2 were up by 9%. With that headwind included, which Johan mentioned, the growth was driven by strong performances in West and Central and a slightly slower performance in Region North. I'm going to come back to the regions individually in a second, just to put a little bit more color around that. But net-net, delivering an EBITDA growth up 12% in the quarter, again, with the FX headwind pushing us back a little bit by 3%. Within that, the EBITDA margin improved marginally in the quarter as well, which is good to see. The new M&A is coming in, enriching the margin and enhancing ongoing operational and synergy efforts within the existing operations. Worth noting, though, is that Q2 also tends to be a seasonally strong quarter for margin. If I look over to the right hand side of this picture, just to quickly summarize. H1. As a whole, we see organic growth up 6% on EBITDA. We see acquired growth delivering 10%, with the FX headwind we've mentioned, but a total adjusted EBITDA growth for H1 of 14%, which is very much a good solid start to the year. If I dive a little bit now into the regions to try and give you a bit more detail, starting with Business Area North. Uh, I think the first and most important thing to say is that the underlying core operations in North, the day-to-day activity servicing the regions, the municipalities, all of those healthcare settings are performing extremely, extremely solidly, extremely well across all of the companies and all of the countries in Region North. We do, however, see an EBITDA decline in the quarter. Um, and that's due to the irregular project-based sales activities that we talked a little bit about in Q1 and is continuing to challenge the figures a bit in Q2, particularly in the defense and preparedness area where we had very strong performance in the same period last year. We have also made good progress with the development of our new larger distribution center in Gothenburg. Uh, that has had its first large CAPEX expenditures, which come into the cash flow, and I'll talk a little bit more about them later. But overall, if you look at H1 as a whole on the right-hand side here, adjusted EBITDA growth is actually down 7%, with net sales down 2% in the first half of the year for those reasons mentioned. And those reasons that I talked about are related to the irregular project-based activities. If I turn to Region West, we see a very nice development, strong organic growth, and improved margins in Region West. A large part of that organic growth is driven by increased patient numbers. We also mentioned this earlier in the year as a result of some larger customer databases that we took over during the second half of 2023. And those increased patient numbers are still flowing through nicely into the figures. We also get a good uplift from the acquisitions that we've done in the region. Uh, the large HSL acquisition we did in February this year, is also fitting nicely into the numbers and performing well in line with expectations. The EBITDA margin is also strengthened a little in the region. Uh, again, a mix of different activities contributing to that, both the organic synergy benefits we see from increased cooperation between our companies, especially within the home care hub that we're seeing developing very nicely in Region West, but also activities across the group with looking at product mix and how we enrich that across our companies. So H1 as a whole, 31% adjusted EBITDA growth, sales growth of 17% in the same period, and then the third of our region's business area, central. Also, we have some good growth figures to present here, primarily driven by the high pace of acquisition activity that we see in Central. So sales are up 25% in the quarter. EBITDA is up 61% in the quarter. And as I say, M&A is a big part of that driver. We also see improved EBITDA margins moving up towards the margins that we observe in the other regions. And that comes again from a variety of activities. Um, the new M&A is coming in, enriching the mix. Um, but we've also had quite a focus on our organic business and the margin within our organic business in the Central region as well. And that's meant that we have been prepared to sacrifice a little bit of revenue growth to get margins up in the region. So overall, H1 EBITDA growth shows an adjusted EBITDA growth of 68% and a net sales growth of 31%. If I turn briefly now here on page ten to the R/RK (EBITA/NWC) metric. This is, as we've talked a lot about in the past, our key internal performance metric, making sure that we're focused on efficient working capital utilization. And again, we're pleased to see that it remains well above our Asker target of 15%. And it's also, of course, an area that we continue to put a lot of effort into with our new companies, our M&A coming into the group. A word or two on the cash flow as well. Um, we see slightly lower operating cash flow compared to the high levels observed in Q2 2024. Um, and actually in 2024, the comparable period, we did have relatively low levels of working capital and very high levels of cash inflow. Again, relating in large part to these project-based sales in North that I've talked about before, we got paid for a lot of the activity that we'd done all the way through H1, and a lot of that money came in during Q2 2024. So the slightly lower level that you see in Q2 2025 is more about the comparables than anything to do with Q2 2025 on a standalone basis. I mentioned earlier, we have had the first of the larger investments in the Gothenburg distribution center. Um, we also paid to take over some distribution rights, and there are some interesting new products coming into the portfolio within the Baltic region that we look forward to delivering strongly in the future. So that was the paid acquisition. Um, the other large chunk of that, -160 million, comes from the earnouts, the contingent considerations that we've paid for previous acquisitions that we've done. And then you see the financing is a large positive 730 million that you see there. That is actually us drawing down cash from our revolving credit facility to pay for the acquisitions that came in early July, primarily Scan Modul. So actually, that money has already been spent in the early weeks of July to complete the acquisition of Scan Modul. And then a final page from me before I hand it back to Johan. The leverage levels are remaining at a relatively low level of 1.8x; since the comparable period, the net debt has obviously risen a little, but we've done more than that through that period. But we brought in, uh, capital through the equity issue at the time of the IPO. But at the same time, obviously, the group has grown strongly and the EBITDA has risen through that period. So the net effect of those two, uh, is that the net debt to EBITDA ratio is at 1.8 as of the end of June, and as Johan mentioned earlier, the attractive pipeline is good because we have a little bit of headroom now within the leverage to, uh, take advantage of that attractive pipeline. All right. I think I'll leave it there, Joanna, and pass it back to you.

Johan Falk
15:16 - 16:22

That is actually us drawing down cash from our revolving credit facility to pay for the acquisitions that came in early July, primarily Scan Modul. Tom. That is actually us drawing down cash from our revolving credit facility to pay for the acquisitions that came in early July, primarily Scan Modul. To summarize this before we go into Q&A. We see this as a steady performance in the quarter, with some headwinds from translation effects and FX. But our operational performance is where it should be. And we're picking up speed in our second engine, M&A. So, it's been a good quarter for us as I see it. We are well on track with the acquisitions overall, but even from that position, we're picking up speed. So looking back at the last 12 months, we have done 16 acquisitions even during this, you know, IPO period. So we have added 2.5 billion SEK. Um, so that's, um, that to me, is where we should be. Maybe a little bit better. So overall, a strong balance sheet gives us good confidence that we will continue to run these twin engines in a good way going forward. So I think we'll leave it there and open up the floor for questions.

Operator
16:26 - 16:45

He wishes to ask a question. Please dial the pound key on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial the pound key on your telephone keypad. The next question comes from Karl Ragnerstam from Nordea. Please go ahead.

Karl Ragnerstam
16:48 - 17:39

Good morning. It's Califano. Um, a few questions, if I may. Uh, firstly, coming back to North, you obviously talked about the challenging comparisons from the defense volumes last year. Could you try to quantify what impact it had in the quarter and also help us understand what the like-for-like would look like without it in the comparisons? Just to understand, you mentioned obviously that it's underlying development is quite nice, but it would be beneficial to get some numbers on it if possible. And on that note as well, um, obviously uh, I mean, we have seen, I guess, maybe not. The wording is not 'shortfall,' but we have seen a lack of defense volumes lately. Why do you think it's the case? And when do you think it might return? So a couple of questions on that. Sorry.

Thomas Moss
17:40 - 19:01

Yep. I can, uh, maybe start on the number side of it. Carl. Yeah. Uh, it's difficult to put an absolutely precise, exact number on it because obviously there are a number of different contracts and different call-offs occurring. But if I were to give you a rough figure, I would talk about probably a couple of hundred million in sales SEK that we are missing on a year-on-year comparison basis within the quarter. Um, I think in terms of your question about when it will come and what we can expect. I think as we've said, we set it at Q1. We said again in the report today, you know, this is clearly an area that's very interesting going forward. There is a lot of activity. There's a lot of noise. You know, we all read the newspapers. We see what's, uh, what's potentially coming. To predict exactly when it will hit is much more difficult for us. Um, I think if we're honest with ourselves, we are a little bit surprised by how slow it has been in the first half of the year. Um, but that doesn't mean that our sort of medium-term confidence is any less than it has been. We believe that the area is interesting and it will come and we are well positioned. We have done a good job with our customers so far. So, there's no reason not to be confident over the medium term. Yes, it's a little bit difficult to predict at the moment.

Karl Ragnerstam
19:03 - 19:10

Um, and do you have exclusivity on those volumes, or have you seen them being delivered by someone else, or how does it work?

Thomas Moss
19:11 - 19:23

No, we definitely haven't seen them being delivered by anyone else. Um, but that's not to say that we have exclusivity either. Um, but, but I think it is.

Karl Ragnerstam
19:23 - 19:24

If you share, I guess.

Thomas Moss
19:24 - 19:30

Yeah, it seems to be relatively slow-moving in the ordering process, essentially.

Karl Ragnerstam
19:32 - 19:50

Sure. But, yes, it's a bit difficult to predict at the moment. That's very clear. Um, could you also talk a bit about the distribution rights you took over in, in the Baltics? What product subsegments is it related to? Could you do some kind of Asker magic as you did in the client list in West as well? Or how does it work with this one?

Unknown 1
19:50 - 19:53

Yes, they are orthopedic products.

Thomas Moss
19:53 - 20:23

Uh, nothing sort of super complicated, but, yeah, orthopedic implant products, highly valued, highly regarded, highly respected within the Baltic region. Um. Um. Profitable products. Products that fit nicely into our existing mix. So, um, we feel very. Yeah, we feel very optimistic and happy about the portfolio expansion and the mix expansion that they give us within our Baltic business.

Karl Ragnerstam
20:24 - 20:27

And the size. Is it possible to provide any financial details?

Thomas Moss
20:29 - 20:50

Uh, I think that's perhaps getting a little bit too specific. You can read from the CapEx that we've spent approximately 100 million SEK to acquire them. So you can perhaps draw some conclusions from that in terms of margins and revenues. But I don't want to go too specifically into that.

Karl Ragnerstam
20:52 - 21:14

That's very clear. And looking at the gross margin, it continued to strengthen, reaching close to 41%. Uh, would you say that the 160 basis point delta is mainly a function of M&A, or is it resulting in mixed effects to consider? And also, you're comfortable at the current level to maintain it or even expand it further from here. Or. Yeah, it would be good to hear more about the dynamics.

Thomas Moss
21:15 - 22:13

Yeah. Um, I think there are a number of different things going on there. But broadly speaking, yes, the M&A that we buy tend to come in at slightly higher gross margins than the existing core of the Asker group companies. Um, they do also tend to come in with slightly higher operating expenses as well, slightly lower down the P&L. Um, but net, net, they are still a positive contributor at an EBITDA margin level as well. So, um, gross margins? Uh, yes. I think we can expect some further progress depending on the M&A that we do and how they come in. But I don't think we should expect any radical upward steps from there. I think the sort of business we are involved in, the activities we're engaged with, and the way we work contribute to gross margins that are at or slightly above 40%, which are quite healthy.

Karl Ragnerstam
22:15 - 22:18

Um, sure. That's very good. That's all from me. Thank you.

Unknown 2
22:18 - 22:19

Thanks. Thanks.

Operator
22:23 - 22:48

As a reminder, if you wish to ask a question, please dial the pound key on your telephone keypad. There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.

Johan Falk
22:50 - 23:04

All right. I'm happy to hear that people want to go back to the beach and have a good time. Um, but thanks for calling in and listening. And, um, I look forward to meeting you next quarter. Thank you.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…